Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01375036 · ClinicalTrials.gov registry record
Registry to Monitor the Susceptibility to Aztreonam of Pseudomonas Aeruginosa Isolates From Cystic Fibrosis Patients
A clinical trial, sponsored by Gilead Sciences.
- Completed
- Registry status
- 510
- Enrollment target
NCT01375036: Completed study, sponsored by Gilead Sciences.
NCT01375036 is a clinical trial that has completed, run by Gilead Sciences. The registered enrollment target is 510 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01375036 has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- 510 participants
- Enrollment target
Study Summary
This is a prospective, longitudinal, 5-year study that will enroll participants from the existing Cystic Fibrosis Foundation (CFF) patient registry. Each enrolled participant will provide samples for microbiological evaluation, obtained upon enrollment and then once per year thereafter for 5 years.
Primary Outcome
This proportion will be compared annually over 5 years.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 510 participants |
| Start Date | 2011-08 |
| Est. Completion | 2016-12 |
What the finished NCT01375036 record still lists
NCT01375036 is an observational study that tracks outcomes without assigning an intervention. The registered 510 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01375036 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01375036 about?
NCT01375036 is a clinical study titled "Registry to Monitor the Susceptibility to Aztreonam of Pseudomonas Aeruginosa Isolates From Cystic Fibrosis Patients". This is a prospective, longitudinal, 5-year study that will enroll participants from the existing Cystic Fibrosis Foundation (CFF) patient registry. Each enrolled participant will provide samples for microbiological evaluation, obtained upon enrollment and then once per year thereafter for 5 years.
What is the current status of trial NCT01375036?
This trial is currently completed. The enrollment target is 510 participants. The study started on 2011-08. Estimated completion is 2016-12.
Who is sponsoring clinical trial NCT01375036?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03922542 · 510 participants · Phase 2
Comparison of Standard vs. Accelerated Corneal Crosslinking
- NCT04634552 · 510 participants · Phase 2
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- NCT05164744 · 510 participants
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
- NCT05451004 · 510 participants · Phase 3
SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia